Role of Hedgehog Signaling Pathways in Multipotent Mesenchymal Stem Cells Differentiation
Cell Transplant. 2024 Jan-Dec;33:9636897241244943. doi: 10.1177/09636897241244943.ABSTRACTMultipotent mesenchymal stem cells (MSCs) have high self-renewal and multi-lineage differentiation potentials and low immunogenicity, so they have attracted much attention in the field of regenerative medicine and have a promising clinical application. MSCs originate from the mesoderm and can differentiate not only into osteoblasts, cartilage, adipocytes, and muscle cells but also into ectodermal and endodermal cell lineages across embryonic layers. To design cell therapy for replacement of damaged tissues, it is essential to understa...
Source: Cell Transplantation - May 2, 2024 Category: Cytology Authors: Mengyu Wu Junwei Mi Guo-Xin Qu Shu Zhang Yi Jian Chu Gao Qingli Cai Jing Liu Jianxin Jiang Hong Huang Source Type: research
Role of Hedgehog Signaling Pathways in Multipotent Mesenchymal Stem Cells Differentiation
Cell Transplant. 2024 Jan-Dec;33:9636897241244943. doi: 10.1177/09636897241244943.ABSTRACTMultipotent mesenchymal stem cells (MSCs) have high self-renewal and multi-lineage differentiation potentials and low immunogenicity, so they have attracted much attention in the field of regenerative medicine and have a promising clinical application. MSCs originate from the mesoderm and can differentiate not only into osteoblasts, cartilage, adipocytes, and muscle cells but also into ectodermal and endodermal cell lineages across embryonic layers. To design cell therapy for replacement of damaged tissues, it is essential to understa...
Source: Cell Transplantation - May 2, 2024 Category: Cytology Authors: Mengyu Wu Junwei Mi Guo-Xin Qu Shu Zhang Yi Jian Chu Gao Qingli Cai Jing Liu Jianxin Jiang Hong Huang Source Type: research
Role of Hedgehog Signaling Pathways in Multipotent Mesenchymal Stem Cells Differentiation
Cell Transplant. 2024 Jan-Dec;33:9636897241244943. doi: 10.1177/09636897241244943.ABSTRACTMultipotent mesenchymal stem cells (MSCs) have high self-renewal and multi-lineage differentiation potentials and low immunogenicity, so they have attracted much attention in the field of regenerative medicine and have a promising clinical application. MSCs originate from the mesoderm and can differentiate not only into osteoblasts, cartilage, adipocytes, and muscle cells but also into ectodermal and endodermal cell lineages across embryonic layers. To design cell therapy for replacement of damaged tissues, it is essential to understa...
Source: Cell Transplantation - May 2, 2024 Category: Cytology Authors: Mengyu Wu Junwei Mi Guo-Xin Qu Shu Zhang Yi Jian Chu Gao Qingli Cai Jing Liu Jianxin Jiang Hong Huang Source Type: research
Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review
Cell Transplant. 2024 Jan-Dec;33:9636897241246351. doi: 10.1177/09636897241246351.ABSTRACTWhile exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) have been approved by the US Food and Drug Administration (FDA) as the first cell-based gene therapies for the treatment of patients 12 years of age and older with sickle cell disease (SCD), this treatment is not universally accessible. Allogeneic hematopoietic stem cell transplant (HSCT) has the potential to eradicate the symptoms of patients with SCD, but a significant obstacle in HSCT for SCD is the availability of suitable donors, particularly human...
Source: Cell Transplantation - April 29, 2024 Category: Cytology Authors: Tahereh Rostami Soroush Rad Mohammad Reza Rostami Seied Amirhossein Mirhosseini Hediyeh Alemi Naghmeh Khavandgar Ghasem Janbabai Azadeh Kiumarsi Amir Kasaeian Seied Asadollah Mousavi Source Type: research
Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review
Cell Transplant. 2024 Jan-Dec;33:9636897241246351. doi: 10.1177/09636897241246351.ABSTRACTWhile exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) have been approved by the US Food and Drug Administration (FDA) as the first cell-based gene therapies for the treatment of patients 12 years of age and older with sickle cell disease (SCD), this treatment is not universally accessible. Allogeneic hematopoietic stem cell transplant (HSCT) has the potential to eradicate the symptoms of patients with SCD, but a significant obstacle in HSCT for SCD is the availability of suitable donors, particularly human...
Source: Cell Transplantation - April 29, 2024 Category: Cytology Authors: Tahereh Rostami Soroush Rad Mohammad Reza Rostami Seied Amirhossein Mirhosseini Hediyeh Alemi Naghmeh Khavandgar Ghasem Janbabai Azadeh Kiumarsi Amir Kasaeian Seied Asadollah Mousavi Source Type: research
Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review
Cell Transplant. 2024 Jan-Dec;33:9636897241246351. doi: 10.1177/09636897241246351.ABSTRACTWhile exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) have been approved by the US Food and Drug Administration (FDA) as the first cell-based gene therapies for the treatment of patients 12 years of age and older with sickle cell disease (SCD), this treatment is not universally accessible. Allogeneic hematopoietic stem cell transplant (HSCT) has the potential to eradicate the symptoms of patients with SCD, but a significant obstacle in HSCT for SCD is the availability of suitable donors, particularly human...
Source: Cell Transplantation - April 29, 2024 Category: Cytology Authors: Tahereh Rostami Soroush Rad Mohammad Reza Rostami Seied Amirhossein Mirhosseini Hediyeh Alemi Naghmeh Khavandgar Ghasem Janbabai Azadeh Kiumarsi Amir Kasaeian Seied Asadollah Mousavi Source Type: research
Alpha-1 Antitrypsin Augmentation Therapy in Chronic Pancreatitis Patients Undergoing Total Pancreatectomy and Islet Autotransplantation: A Randomized, Controlled Study
Cell Transplant. 2024 Jan-Dec;33:9636897241243014. doi: 10.1177/09636897241243014.ABSTRACTStress-induced islet graft loss during the peri-transplantation period reduces the efficacy of islet transplantation. In this prospective, randomized, double-blind clinical trial, we evaluated the safety and efficacy of 60 mg/kg human alpha-1 antitrypsin (AAT) or placebo infusion weekly for four doses beginning before surgery in chronic pancreatitis (CP) patients undergoing total pancreatectomy and islet autotransplantation (TP-IAT). Subjects were followed for 12 months post-TP-IAT. The dose of AAT was safe, as there was no difference...
Source: Cell Transplantation - April 25, 2024 Category: Cytology Authors: Hongjun Wang Wenyu Gou Paul J Nietert Jason Hirsch Jingjing Wang Ahmed Allawi Abd S Mortadha Kelsey Cook Morgan Overstreet Hua Wei David Adams William P Lancaster Katherine A Morgan Charlie Strange Source Type: research
Alpha-1 Antitrypsin Augmentation Therapy in Chronic Pancreatitis Patients Undergoing Total Pancreatectomy and Islet Autotransplantation: A Randomized, Controlled Study
Cell Transplant. 2024 Jan-Dec;33:9636897241243014. doi: 10.1177/09636897241243014.ABSTRACTStress-induced islet graft loss during the peri-transplantation period reduces the efficacy of islet transplantation. In this prospective, randomized, double-blind clinical trial, we evaluated the safety and efficacy of 60 mg/kg human alpha-1 antitrypsin (AAT) or placebo infusion weekly for four doses beginning before surgery in chronic pancreatitis (CP) patients undergoing total pancreatectomy and islet autotransplantation (TP-IAT). Subjects were followed for 12 months post-TP-IAT. The dose of AAT was safe, as there was no difference...
Source: Cell Transplantation - April 25, 2024 Category: Cytology Authors: Hongjun Wang Wenyu Gou Paul J Nietert Jason Hirsch Jingjing Wang Ahmed Allawi Abd S Mortadha Kelsey Cook Morgan Overstreet Hua Wei David Adams William P Lancaster Katherine A Morgan Charlie Strange Source Type: research
Alpha-1 Antitrypsin Augmentation Therapy in Chronic Pancreatitis Patients Undergoing Total Pancreatectomy and Islet Autotransplantation: A Randomized, Controlled Study
Cell Transplant. 2024 Jan-Dec;33:9636897241243014. doi: 10.1177/09636897241243014.ABSTRACTStress-induced islet graft loss during the peri-transplantation period reduces the efficacy of islet transplantation. In this prospective, randomized, double-blind clinical trial, we evaluated the safety and efficacy of 60 mg/kg human alpha-1 antitrypsin (AAT) or placebo infusion weekly for four doses beginning before surgery in chronic pancreatitis (CP) patients undergoing total pancreatectomy and islet autotransplantation (TP-IAT). Subjects were followed for 12 months post-TP-IAT. The dose of AAT was safe, as there was no difference...
Source: Cell Transplantation - April 25, 2024 Category: Cytology Authors: Hongjun Wang Wenyu Gou Paul J Nietert Jason Hirsch Jingjing Wang Ahmed Allawi Abd S Mortadha Kelsey Cook Morgan Overstreet Hua Wei David Adams William P Lancaster Katherine A Morgan Charlie Strange Source Type: research
Alpha-1 Antitrypsin Augmentation Therapy in Chronic Pancreatitis Patients Undergoing Total Pancreatectomy and Islet Autotransplantation: A Randomized, Controlled Study
Cell Transplant. 2024 Jan-Dec;33:9636897241243014. doi: 10.1177/09636897241243014.ABSTRACTStress-induced islet graft loss during the peri-transplantation period reduces the efficacy of islet transplantation. In this prospective, randomized, double-blind clinical trial, we evaluated the safety and efficacy of 60 mg/kg human alpha-1 antitrypsin (AAT) or placebo infusion weekly for four doses beginning before surgery in chronic pancreatitis (CP) patients undergoing total pancreatectomy and islet autotransplantation (TP-IAT). Subjects were followed for 12 months post-TP-IAT. The dose of AAT was safe, as there was no difference...
Source: Cell Transplantation - April 25, 2024 Category: Cytology Authors: Hongjun Wang Wenyu Gou Paul J Nietert Jason Hirsch Jingjing Wang Ahmed Allawi Abd S Mortadha Kelsey Cook Morgan Overstreet Hua Wei David Adams William P Lancaster Katherine A Morgan Charlie Strange Source Type: research
Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects
Cell Transplant. 2024 Jan-Dec;33:9636897241247951. doi: 10.1177/09636897241247951.ABSTRACTHematological toxicity is a severe adverse event (AE) in anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the pathophysiological mechanism underlying prolonged cytopenia and the relationship between persistent cytopenia, efficacy, and AEs after anti-CD19 CAR T cell therapy are unknown. Therefore, this study explored whether persistent cytopenia after anti-CD19 CAR T cell therapy in patients with R/R DLBCL can predict therapeutic efficacy and AEs. Thi...
Source: Cell Transplantation - April 23, 2024 Category: Cytology Authors: Jingyi Li Juan Mu Jia Wang Xin Li Qing Li Yili Jiang Rui Cui Qi Deng Source Type: research
Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects
Cell Transplant. 2024 Jan-Dec;33:9636897241247951. doi: 10.1177/09636897241247951.ABSTRACTHematological toxicity is a severe adverse event (AE) in anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the pathophysiological mechanism underlying prolonged cytopenia and the relationship between persistent cytopenia, efficacy, and AEs after anti-CD19 CAR T cell therapy are unknown. Therefore, this study explored whether persistent cytopenia after anti-CD19 CAR T cell therapy in patients with R/R DLBCL can predict therapeutic efficacy and AEs. Thi...
Source: Cell Transplantation - April 23, 2024 Category: Cytology Authors: Jingyi Li Juan Mu Jia Wang Xin Li Qing Li Yili Jiang Rui Cui Qi Deng Source Type: research
From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept
This study investigates whether the observed effects on PTD stem solely from CNI withdrawal or if belatacept influences PTD independently. The study assessed the impact of tacrolimus and belatacept on insulin secretion in MIN6 cells (a beta cell line) and rat islets. Tacrolimus and belatacept were administered to the cells and islets, followed by assessments of cell viability and insulin secretion. Tacrolimus impaired insulin secretion without affecting cell viability, while belatacept showed no detrimental effects on either parameter. These findings support clinical observations of improved HbA1c upon switching from tacro...
Source: Cell Transplantation - April 22, 2024 Category: Cytology Authors: Quentin Perrier C écile Cottet-Rouselle Marine de-Beaumont Johan Noble Sandrine Lablanche Source Type: research
Overcoming Methodological Challenges for Advancing Stem Cell Therapies in Parkinson's Disease
Cell Transplant. 2024 Jan-Dec;33:9636897241246355. doi: 10.1177/09636897241246355.ABSTRACTThe quest for new and improved therapies for Parkinson's disease (PD) remains of paramount importance, despite previous trial failures. There is a current debate regarding the potential of stem cell research as a therapeutic approach for PD. The studies of dopaminergic fetal stem cells for PD treatment, their design, and the results of the initial surgical placebo-controlled trials were reviewed in this study. Some of the fundamental methodological challenges and possible strategies to resolve them were proposed. In this article, we a...
Source: Cell Transplantation - April 18, 2024 Category: Cytology Authors: Stephen Polgar David I Finkelstein Leila Karimi Source Type: research
Overcoming Methodological Challenges for Advancing Stem Cell Therapies in Parkinson's Disease
Cell Transplant. 2024 Jan-Dec;33:9636897241246355. doi: 10.1177/09636897241246355.ABSTRACTThe quest for new and improved therapies for Parkinson's disease (PD) remains of paramount importance, despite previous trial failures. There is a current debate regarding the potential of stem cell research as a therapeutic approach for PD. The studies of dopaminergic fetal stem cells for PD treatment, their design, and the results of the initial surgical placebo-controlled trials were reviewed in this study. Some of the fundamental methodological challenges and possible strategies to resolve them were proposed. In this article, we a...
Source: Cell Transplantation - April 18, 2024 Category: Cytology Authors: Stephen Polgar David I Finkelstein Leila Karimi Source Type: research
